Background:Poly adenosine-diphosphate-ribose polymerase(PARP)inhibitors(PARPi)have been approved to act as first-line maintenance(FL-M)therapy and as platinum-sensitive recurrent maintenance(PSR-M)therapy for ovarian ...Background:Poly adenosine-diphosphate-ribose polymerase(PARP)inhibitors(PARPi)have been approved to act as first-line maintenance(FL-M)therapy and as platinum-sensitive recurrent maintenance(PSR-M)therapy for ovarian cancer in China for>5 years.Herein,we have analyzed the clinical-application characteristics of olaparib and niraparib in ovarian cancer-maintenance therapy in a real-world setting to strengthen our understanding and promote their rational usage.Methods:A retrospective chart review identified patients with newly diagnosed or platinum-sensitive recurrent ovarian cancer,who received olaparib or niraparib as maintenance therapy at Sichuan Cancer Hospital between August 1,2018,and December 31,2021.Patient medical records were reviewed.We grouped and analyzed patients based on the type of PARPi they used(the olaparib group and the niraparib group)and the line of PARPi maintenance therapy(the FL-M setting and the PSR-M setting).The primary endpoint was the 24-month progression-free survival(PFS)rate.Results:In total,131 patients(olaparib:n=67,51.1%;niraparib:n=64,48.9%)were enrolled.Breast cancer susceptibility genes(BRCA)mutations(BRCA m)were significantly less common in the niraparib group than in the olaparib group[9.4%(6/64)vs.62.7%(42/67),P<0.001],especially in the FL-M setting[10.4%(5/48)vs.91.4%(32/35),P<0.001].The 24-month progression-free survival(PFS)rates in the FL-M and PSR-M settings were 60.4%and 45.7%,respectively.In patients with BRCA m,the 24-month PFS rates in the FL-M and PSR-M settings were 62.2%and 72.7%,respectively.Conclusions:Olaparib and niraparib were effective in patients with ovarian cancer without any new safety signals except for skin pigmentation.In patients with BRCA m,the 24-month PFS of the PARPi used in the PSR-M setting was even higher than that used in the FL-M setting.展开更多
基金This work was supported by grants from the Natural Science Foundation of Sichuan Province(No.2023NSFSC0702)the Basic Research Business Fee Project of Central Universities at the University of Electronic Science and Technology of China(No.ZYGX2022J024).
文摘Background:Poly adenosine-diphosphate-ribose polymerase(PARP)inhibitors(PARPi)have been approved to act as first-line maintenance(FL-M)therapy and as platinum-sensitive recurrent maintenance(PSR-M)therapy for ovarian cancer in China for>5 years.Herein,we have analyzed the clinical-application characteristics of olaparib and niraparib in ovarian cancer-maintenance therapy in a real-world setting to strengthen our understanding and promote their rational usage.Methods:A retrospective chart review identified patients with newly diagnosed or platinum-sensitive recurrent ovarian cancer,who received olaparib or niraparib as maintenance therapy at Sichuan Cancer Hospital between August 1,2018,and December 31,2021.Patient medical records were reviewed.We grouped and analyzed patients based on the type of PARPi they used(the olaparib group and the niraparib group)and the line of PARPi maintenance therapy(the FL-M setting and the PSR-M setting).The primary endpoint was the 24-month progression-free survival(PFS)rate.Results:In total,131 patients(olaparib:n=67,51.1%;niraparib:n=64,48.9%)were enrolled.Breast cancer susceptibility genes(BRCA)mutations(BRCA m)were significantly less common in the niraparib group than in the olaparib group[9.4%(6/64)vs.62.7%(42/67),P<0.001],especially in the FL-M setting[10.4%(5/48)vs.91.4%(32/35),P<0.001].The 24-month progression-free survival(PFS)rates in the FL-M and PSR-M settings were 60.4%and 45.7%,respectively.In patients with BRCA m,the 24-month PFS rates in the FL-M and PSR-M settings were 62.2%and 72.7%,respectively.Conclusions:Olaparib and niraparib were effective in patients with ovarian cancer without any new safety signals except for skin pigmentation.In patients with BRCA m,the 24-month PFS of the PARPi used in the PSR-M setting was even higher than that used in the FL-M setting.
